14.68

1.38% -0.34

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is traded at $14.68, with a volume of 37,226. It is down -1.38% in the last 24 hours and down -10.71% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Previous Close:

$15.02

Open:

$13.41

24h Volume:

37,226

Relative Volume:

1.30

Market Cap:

$97.28M

Revenue:

Net Income/Loss:

$-61.23M

P/E Ratio:

-9.0061

EPS:

-1.63

Net Cash Flow:

$22.49M

1W Performance:

-13.12%

1M Performance:

-10.71%

6M Performance:

-2.29%

1Y Performance:

+89.01%

1-Day Range:

$13.41

$15.24

1-Week Range:

$13.41

$17.04

52-Week Range:

$7.692

$19.93

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(833) 409-4583

Address

TWO TOWER PLACE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-12-06

Latest SEC Filings

ASMB's Discussions on Twitter

Compare ASMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASMB	14.49	97.28M	0	-61.23M	22.49M	-1.63
VRTX	447.65	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.99	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	588.27	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.49	24.49B	3.30B	-501.07M	1.03B	11.54

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

Nov 17, 2024

(ASMB) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Adjusts Stake in Assembly Biosciences Inc - GuruFocus.com

Nov 14, 2024

HC Wainwright Has Optimistic Outlook of ASMB FY2024 Earnings - MarketBeat

Nov 14, 2024

Nov 13, 2024

Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 51.2% in October - MarketBeat

Nov 13, 2024

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers - Simply Wall St

Nov 13, 2024

Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates - Yahoo Finance

Nov 13, 2024

Nov 12, 2024

Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World

Nov 12, 2024

Nov 08, 2024

Assembly Biosciences: Q3 Earnings Snapshot - CTPost

Nov 08, 2024

Nov 07, 2024

Assembly Biosciences initiates at-the-market equity program - Investing.com India

Nov 07, 2024